Drug Companies Argue Patent Enablement Standard In High Court Briefs
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals’ finding that two genus cholesterol drug patents of Amgen Inc. were invalid for lack of enablement comports with statutory law and...To view the full article, register now.
Already a subscriber? Click here to view full article